Entera Bio (ENTX) director Ellis Sean buys 18,000 ordinary shares

Rhea-AI Filing Summary

Entera Bio Ltd. director Ellis Sean reported buying 18,000 ordinary shares on February 9, 2026. The purchase was coded as an open-market or private purchase at a weighted average price of $1.24 per share, bringing his directly held stake to 178,098 ordinary shares.

The shares were acquired in multiple trades, with prices ranging from $1.18 to $1.299 per share. Sean is listed as a director of Entera Bio, and the filing shows the ownership as held directly rather than through an intermediary entity.

Insider Trade Summary

Net Buyer: 18,000 shares ($22,320)

Net Buy 1 txn

Insider Ellis Sean

Role Director

Bought 18,000 shs ($22K)

Type	Security	Shares	Price	Value
Purchase	Ordinary Shares, par value NIS 0.0000769 per share	18,000	$1.24	$22K

Holdings After Transaction: Ordinary Shares, par value NIS 0.0000769 per share — 178,098 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ellis Sean

(Last) (First) (Middle)

KIRYAT HADASSAH

MINRAV BUILDING, FIFTH FLOOR

(Street)

JERUSALEM L3 9112002

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Entera Bio Ltd. [ ENTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/09/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares, par value NIS 0.0000769 per share	02/09/2026		P		18,000	A	$1.24(1)	178,098	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.18 to $1.299 inclusive. The reporting person undertakes to provide to Entera Bio Ltd., an Israeli company ("Entera Bio"), any security holder of Entera Bio, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

	/s/ Dana Yaacov-Garbeli, Attorney-in-Fact	02/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Entera Bio (ENTX) report for director Ellis Sean?

Entera Bio reported that director Ellis Sean bought 18,000 ordinary shares. The transaction occurred on February 9, 2026, and was coded as a purchase, increasing his direct holdings to 178,098 ordinary shares in the company after the reported transaction.

At what price did Ellis Sean buy Entera Bio (ENTX) shares on February 9, 2026?

The Form 4 shows a weighted average purchase price of $1.24 per share. A footnote explains these 18,000 ordinary shares were bought in multiple trades, with individual prices ranging from $1.18 to $1.299 per share, all on the same transaction date.

How many Entera Bio (ENTX) shares does Ellis Sean own after the reported Form 4 purchase?

After the transaction, director Ellis Sean beneficially owns 178,098 ordinary shares. The filing classifies this ownership as direct, meaning the shares are held in his name rather than through an indirect entity such as a trust or partnership.

What type of security did Ellis Sean acquire in Entera Bio (ENTX)?

The filing states that Ellis Sean acquired ordinary shares of Entera Bio, each with a par value of NIS 0.0000769. These are non-derivative equity securities, reported in Table I of the Form 4 as directly owned following the February 9, 2026 purchase.

Does the Entera Bio (ENTX) Form 4 explain the price range for Ellis Sean’s purchase?

Yes. A footnote clarifies that the reported $1.24 price is a weighted average. The 18,000 ordinary shares were purchased in multiple trades, with execution prices ranging between $1.18 and $1.299 per share, all inclusive, on the same transaction date.

Who signed the Entera Bio (ENTX) Form 4 reporting Ellis Sean’s share purchase?

The Form 4 is signed by Dana Yaacov-Garbeli as attorney-in-fact. This indicates the filing was submitted under a power of attorney on behalf of reporting person Ellis Sean, documenting his February 9, 2026 acquisition of Entera Bio ordinary shares.